Year All2024202320222021202020192018201720162015 Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board July 26, 2022 Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products June 29, 2022 Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders June 2, 2022 Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors May 18, 2022 Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting May 17, 2022 Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022 May 12, 2022 Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting May 2, 2022 Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference April 28, 2022 Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 March 10, 2022 Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 1, 2022
Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board July 26, 2022
Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products June 29, 2022
Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting May 17, 2022
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022 May 12, 2022
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting May 2, 2022
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 March 10, 2022
